CancerLONGEVITINCT05645510
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
An observational study of Cancer and Tyrosine Kinase Mutation, run by University of Alberta at 1 site in Canada.
Trial summary
People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Cancer, Tyrosine Kinase Mutation, Breast Cancer
- How many people
- 75 participants
- Where
- 1 siteCanada
- Study dates
- 24 Nov 2022to 9 Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: people with cancer taking oral anti-cancer agents over the long term
Who may be able to join
None listed.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Meredith Porter Hogg, MN contact
Canada1 site, 1 recruiting
- Recruiting
Edith Pituskin
Edmonton, Alberta, T6G 1C9
Edith Pituskin, PhD, 7804328221, pituskin@ualberta.ca
About this study
People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.
Read the detailed description
Participants ill be scheduled for an in-person, telephone or computer video interview with the researcher(s). They will be asked about their experiences receiving targeted anti-cancer treatments. Then over the next 3 months, participants will be asked to think about how receiving these cancer treatments affects daily living and to create a 'metaphor'. Metaphors may be composed with any mix of visual, verbal, musical or other works participants feel expresses and brings their experiences to life.
- Conditions
- Cancer, Tyrosine Kinase Mutation, Breast Cancer, Melanoma, Multiple Myeloma, Chronic Leukemia
- Medical subject headings
- Neoplasms, Breast Neoplasms, Melanoma, Multiple Myeloma, Prostatic Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Lung Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Interview
Interview to learn the experiences of people living with incurable cancers
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2022
- Study start24 Nov 2022
- Primary completion9 Jun 2026 (estimated)
- Study completion9 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Social Sciences and Humanities Research Council of Canada
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05645510
- Sponsor's protocol ID
- HREBA.CC-22-0196
- Acronym
- LONGEVITI
- Status last verified
- May 2026
- First submitted
- 30 Nov 2022
- Last updated
- 11 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
- ClinicalTrials.gov ID
- NCT05645510
- Acronym / sponsor ID
- LONGEVITI / HREBA.CC-22-0196
- Conditions
- Cancer, Tyrosine Kinase Mutation, Breast Cancer, Melanoma, Multiple Myeloma, Chronic Leukemia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- Social Sciences and Humanities Research Council of Canada
- Study start
- 24 Nov 2022 (actual)
- Primary completion
- 9 Jun 2026 (estimated)
- Study completion
- 9 Jun 2026 (estimated)
- First posted
- 9 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.
Detailed description
Participants ill be scheduled for an in-person, telephone or computer video interview with the researcher(s). They will be asked about their experiences receiving targeted anti-cancer treatments. Then over the next 3 months, participants will be asked to think about how receiving these cancer treatments affects daily living and to create a 'metaphor'. Metaphors may be composed with any mix of visual, verbal, musical or other works participants feel expresses and brings their experiences to life.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- people with cancer taking oral anti-cancer agents over the long term
Key inclusion criteria (0 listed)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Interview
Time frame: 3 months
Interview to learn the experiences of people living with incurable cancers
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2026.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Meredith Porter Hogg, MN contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Tyrosine Kinase Mutation, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Edith Pituskin, PhD (7804328221, pituskin@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interview (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.